{"id":"NCT02631876","sponsor":"ImmunoGen, Inc.","briefTitle":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","officialTitle":"FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-02","primaryCompletion":"2019-01","completion":"2020-01","firstPosted":"2015-12-16","resultsPosted":"2020-06-09","lastUpdate":"2020-10-14"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Ovarian Cancer"],"interventions":[{"type":"DRUG","name":"Mirvetuximab soravtansine","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pegylated liposomal doxorubicin","otherNames":[]},{"type":"DRUG","name":"Topotecan","otherNames":[]}],"arms":[{"label":"Mirvetuximab Soravtansine","type":"EXPERIMENTAL"},{"label":"Investigator's Choice (IC) Chemotherapy","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study","timeFrame":"From the date of randomization until the time of death or PD (maximum exposure: 86.9 weeks for mirvetuximab soravtansine arm and 62.9 weeks for IC chemotherapy arm)","effectByArm":[{"arm":"Mirvetuximab Soravtansine","deltaMin":4.14,"sd":null},{"arm":"Investigator's Choice (IC) Chemotherapy","deltaMin":4.44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":131,"countries":["United States","Belgium","Bosnia and Herzegovina","Canada","Czechia","France","Ireland","Italy","Russia","Serbia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["33667670"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":243},"commonTop":["Nausea","Diarrhoea","Fatigue","Vision blurred","Abdominal pain"]}}